1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors

Almost No Patients Required Post-Treatment Factor Replacement Therapy

 
• By Alaric DeArment

UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.

Hemophilia_525478450_1200.jpg
Freeline announced data from the Phase I/II study of its hemophilia B gene therapy. • Source: Shutterstock

Freeline Therapeutics Holdings PLC is touting data from its Phase I/II clinical trial of FLT180a (vebrinacogene setparvovec) in hemophilia B, showing that virtually none of the patients in the study required Factor IX (FIX) replacement therapy after treatment with the company’s gene therapy.

London-based Freeline plans to move FLT180a into a pivotal Phase IIb/III study, which it will

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas